Charles J. Casamento net worth and biography

Charles Casamento Biography and Net Worth

Director of Relmada Therapeutics

Since 2007 Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group. He was president and CEO of Osteologix from October 2004 until April 2007. Mr. Casamento was the founder of Questcor Pharmaceuticals where he was president, CEO and chairman. In 2014 Questcor was acquired by Mallinckrodt for approximately $6 Billion. At RiboGene Inc. he was president, CEO and chairman and he was also co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). Indevus was eventually acquired by Endo for approximately $800 Million. He has held senior management positions at Genzyme Corporation, where he was Senior Vice President and General Manager for Biochemicals and Pharmaceuticals, American Hospital Supply, where he was Vice President of Business Development for the Critical Care Division, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. During his career he has been a Director of eleven other pharmaceutical/biotechnology companies and has been on the board of two not for profit organizations. He holds a bachelor’s degree in Pharmacy from Fordham University and an M.B.A. from Iona College. Mr. Casamento also serves as the Chairman of the company’s Audit Committee.

What is Charles J. Casamento's net worth?: The estimated net worth of Charles J. Casamento is at least $4,717.70 as of September 9th, 2024. Mr. Casamento owns 13,000 shares of Relmada Therapeutics stock worth more than $4,718 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Casamento may own. Learn More about Charles J. Casamento's net worth.
How do I contact Charles J. Casamento?: The corporate mailing address for Mr. Casamento and other Relmada Therapeutics executives is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. Relmada Therapeutics can also be reached via phone at (786) 629-1376 and via email at [email protected]. Learn More on Charles J. Casamento's contact information.
Has Charles J. Casamento been buying or selling shares of Relmada Therapeutics?: Charles J. Casamento has not been actively trading shares of Relmada Therapeutics within the last three months. Most recently, on Monday, September 9th, Charles J. Casamento bought 13,000 shares of Relmada Therapeutics stock. The stock was acquired at an average cost of $2.56 per share, with a total value of $33,280.00. Following the completion of the transaction, the director now directly owns 13,000 shares of the company's stock, valued at $33,280. Learn More on Charles J. Casamento's trading history.
Who are Relmada Therapeutics' active insiders?: Relmada Therapeutics' insider roster includes Charles Casamento (Director), and Maged Shenouda (CFO). Learn More on Relmada Therapeutics' active insiders.
Are insiders buying or selling shares of Relmada Therapeutics?: In the last twelve months, Relmada Therapeutics insiders bought shares 10 times. They purchased a total of 243,476 shares worth more than $779,959.33. The most recent insider tranaction occured on September, 11th when CEO Sergio Traversa bought 51,407 shares worth more than $153,706.93. Insiders at Relmada Therapeutics own 18.0% of the company. Learn More about insider trades at Relmada Therapeutics.
Information on this page was last updated on 9/11/2024.

Charles J. Casamento Insider Trading History at Relmada Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/9/2024	Buy	13,000	$2.56	$33,280.00	13,000
9/22/2021	Sell	6,600	$29.00	$191,400.00
7/15/2021	Sell	3,300	$31.54	$104,082.00	5,854
6/1/2021	Sell	3,000	$33.34	$100,020.00	9,430
4/1/2021	Sell	3,000	$35.43	$106,290.00	14,641
2/1/2021	Sell	3,000	$33.63	$100,890.00
11/2/2020	Sell	3,000	$30.29	$90,870.00	49,173
9/1/2020	Sell	3,000	$34.74	$104,220.00	55,173
8/3/2020	Sell	3,000	$35.74	$107,220.00	34,000
7/1/2020	Sell	3,000	$43.89	$131,670.00

Charles J. Casamento Buying and Selling Activity at Relmada Therapeutics

Relmada Therapeutics Company Overview

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Today's Range

Now: $0.36

$0.34

$0.38

50 Day Range

MA: $2.52

$0.35

$3.64

2 Week Range

Now: $0.36

$0.34

$7.22

Volume

424,888 shs

Average Volume

341,736 shs

Market Capitalization

$10.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.